NCT03344172 - Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions

Pancreatic Cancer Resectable

Interventions

DRUG

Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab

Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)

DRUG

Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine

Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh